In August 2022, U.S. President Joe Biden signed the Inflation Reduction Act (IRA) of 2022 into law. As the name suggests, the bill aims to combat the rising cost of living through several measures, including:
- Reducing healthcare costs: Expanding health insurance subsidies and cutting prescription drug prices for Medicare recipients
- Incentivizing clean energy: Offering tax credits and rebates to consumers who wish to purchase electric vehicles or make energy-efficient upgrades to their home
However, as the bill does not address the key drivers of the cost-of-living crisis—namely, soaring food prices and energy prices—its impact on inflation will likely be negligible. “We believe the drug pricing provisions will have little near-term impact on the CPI,” explained Michael Feroli, Chief U.S. Economist at J.P. Morgan. “And if there are longer-run beneficial effects for the supply-side of the economy, that’s a growth issue, not an inflation issue. In the long run, inflation is determined by Fed policy.”